TERRI REMBUSKOS: Open Payments
NPI 1689757627 · LOS ALAMITOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$882 in 36 payments from 13 companies in 2025. Trend: 2023 $245 · 2024 $445 · 2025 $882
Food & beverage: $882
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 5 | $140 |
| Madrigal Pharmaceuticals | 5 | $138 |
| Aimmune Therapeutics, Inc. | 6 | $127 |
| Janssen Biotech, Inc. | 5 | $119 |
| ABBVIE INC. | 4 | $88 |
| GENZYME CORPORATION | 2 | $58 |
| Phathom Pharmaceuticals, Inc. | 2 | $55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $46 |
| Lilly USA, LLC | 1 | $27 |
| Novo Nordisk Inc | 1 | $26 |
Products named: IBSRELA, REZDIFFRA, TREMFYA, VOWST, DUPIXENT, RINVOQ, VOQUEZNA, ZENPEP.
Industry payments across CA — which companies pay providers there.
